Molecular characterization of RBG-NLRP3 binding interaction

Exploratory Score: 0.900 Price: $0.50 atherosclerosis purified proteins and molecular simulation Status: proposed

What This Experiment Tests

Exploratory experiment designed to discover new patterns targeting NLRP3 in purified proteins and molecular simulation. Primary outcome: binding affinity and interaction site identification

Description

This molecular study characterized the direct binding interaction between RBG and the NLRP3 protein using multiple complementary approaches. Molecular docking simulations were performed to predict binding sites, followed by surface plasmon resonance (SPR) assays to measure binding kinetics and affinity. Pull-down assays were conducted to confirm the physical interaction between RBG and NLRP3. The study identified that RBG forms a non-covalent interaction with the CYS-279 residue of NLRP3, which effectively hinders inflammasome assembly and confirms RBG's role as a potent NLRP3 inhibitor.

TARGET GENE
MODEL SYSTEM
purified proteins and molecular simulation
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
NLRP3 inflammasome assembly
SOURCE
extracted_from_pmid_40258472
PRIMARY OUTCOME
binding affinity and interaction site identification

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

NLRP3-Coupled Senomorphic Cycling TherapytherapeuticNLRP3 Inflammasome-Activated MicrogliacellNLRP3 InflammasomeentityNLRP3 Inflammasome Validation Study in Parkinson'sexperimentNLRP3 Inflammasome Hypothesis in Parkinson's Diseahypothesisnlrp3-inflammasomemechanismNLRP3 Inflammasome Activation Pathway in NeurodegemechanismNLRP3 Inflammasome Pathway in NeurodegenerationmechanismNLRP3 Inflammasome Pathway in NeurodegenerationmechanismNLRP3 (NLR Family Pyrin Domain Containing 3)proteinNLRP3 Inflammasome Inhibitorstherapeuticsnlrp3-inflammasome-activated-microgliacell_typeNLRP3 Inflammasome Inhibitors for Parkinson's DisemechanismNLRP3 Inflammasome Inhibitors for NeurodegenerativtherapeuticNLRP3 Inhibitors in Parkinson's Disease: Research mechanism

Protocol

molecular docking simulations, surface plasmon resonance (SPR) binding assays, and pull-down studies to characterize RBG-NLRP3 interaction

Expected Outcomes

Expected to identify specific binding site and confirm direct interaction. Results identified a non-covalent interaction between RBG and the CYS-279 residue of NLRP3, confirming RBG as a potent NLRP3 inhibitor

Success Criteria

demonstration of direct binding and identification of binding site

Related Hypotheses (2)

NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplification0.657
NLRP3/Mitophagy Coupling Modulation0.619

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.